Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

1.0K
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
1.0K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

1.1K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.1K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

504
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
504
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

994
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
994
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

887
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
887
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

569
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
569

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infection of Rhesus Macaques with O'nyong-nyong virus UVRI-0804 recapitulates key aspects of human clinical disease.

PLoS neglected tropical diseases·2026
Same author

Structure-guided design of potent and selective covalent inhibitors of SARS-CoV-1 and SARS-CoV-2 papain-like proteases with antiviral activity.

European journal of medicinal chemistry·2026
Same author

Novel computational pipeline to identify target sites for broad spectrum antiviral drugs.

Antiviral research·2025
Same author

Identification of spirodioxolane nsP2 helicase inhibitors with antialphaviral activity.

RSC medicinal chemistry·2025
Same author

<i><b>N</b></i>-Alkyl Sulfamates as a New Class of nsP2 Cysteine Protease Inhibitors with Broad-Spectrum Antialphaviral Activity.

Journal of medicinal chemistry·2025
Same author

Insulin deficiency inhibits vaccine-mediated antibody and germinal center B-cell formation in mice.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Feb 4, 2026

Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS
07:20

Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS

Published on: September 7, 2016

11.6K

Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis.

Lisa E Gralinski1, Timothy P Sheahan1, Thomas E Morrison2

  • 1Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA.

Mbio
|October 11, 2018
PubMed
Summary
This summary is machine-generated.

The complement system exacerbates severe acute respiratory syndrome coronavirus (SARS-CoV) disease by driving inflammation, not viral replication. Inhibiting complement may offer a novel therapeutic strategy for SARS-CoV infections.

Keywords:
SARS-CoVanimal modelscomplementcoronavirusrespiratory viruses

More Related Videos

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome
04:45

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Published on: June 2, 2022

2.8K
Oleic Acid-Injection in Pigs As a Model for Acute Respiratory Distress Syndrome
06:06

Oleic Acid-Injection in Pigs As a Model for Acute Respiratory Distress Syndrome

Published on: October 26, 2018

10.4K

Related Experiment Videos

Last Updated: Feb 4, 2026

Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS
07:20

Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS

Published on: September 7, 2016

11.6K
Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome
04:45

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Published on: June 2, 2022

2.8K
Oleic Acid-Injection in Pigs As a Model for Acute Respiratory Distress Syndrome
06:06

Oleic Acid-Injection in Pigs As a Model for Acute Respiratory Distress Syndrome

Published on: October 26, 2018

10.4K

Area of Science:

  • Immunology
  • Virology
  • Pathogenesis

Background:

  • Severe acute respiratory syndrome coronavirus (SARS-CoV) infection can lead to acute respiratory distress syndrome (ARDS), characterized by immune-driven pathologies.
  • The complement system is a key component of the innate immune response, crucial for host defense against various pathogens.

Purpose of the Study:

  • To investigate the role of the complement system in SARS-CoV-induced lung pathology and disease severity.
  • To determine if complement activation contributes to protective or detrimental outcomes during SARS-CoV infection.

Main Methods:

  • Utilized a mouse model of SARS-CoV infection (C57BL/6J mice).
  • Employed mice deficient in C3 (C3-/-) to assess the impact of complement absence on disease progression.
  • Quantified viral loads, immune cell infiltration (neutrophils, monocytes), respiratory dysfunction, weight loss, cytokine/chemokine levels, and lung pathology.

Main Results:

  • SARS-CoV-infected C3-/- mice showed significantly reduced weight loss and respiratory dysfunction compared to controls, despite equivalent lung viral loads.
  • Absence of C3 led to markedly fewer neutrophils and inflammatory monocytes in the lungs.
  • Reduced lung pathology and lower systemic and local cytokine/chemokine levels were observed in C3-/- mice.

Conclusions:

  • The complement system acts as a significant mediator of SARS-CoV-induced disease, promoting inflammation rather than controlling viral replication.
  • Complement activation drives a systemic inflammatory response, contributing to the immunopathology of SARS-CoV infection.
  • Inhibiting complement signaling presents a potential therapeutic avenue for managing SARS-CoV disease.